glp 1 gip glucagon triple agonist retatrutide glp-1 phase 3 2025 Dual and Triple Gut Peptide Agonists Retatrutide: The triple agonist powering

(See Fig

[10] [11] Other potential adverse effects observed with GLP-1 receptor agonists include: Injection site reactions: Redness, swelling, or discomfort at the injection site Fatigue and dizziness: Particularly during the initial treatment period Increased heart rate: A modest elevation in resting heart rate has been noted with GLP-1 agonists [12] [13] Hypoglycaemia: Risk is low when used alone but increases if combined with insulin or sulphonylureas Serious safety considerations require careful monitoring

Ongoing research endeavors aim to optimize their therapeutic use, delineate patient-specific treatment paradigms, and explore novel therapeutic applications

Iron, magnesium, selenium, and B-complex vitamins support enzymatic velocity and mitochondrial metabolic throughput [100]

doi: 10.1016/j.jdcr.2024.08.018